Solid preparations containing 6,7-unsaturated-7-carbamoylmorphinan derivatives

JP7582961B2Active Publication Date: 2024-11-13SHIONOGI & CO LTD
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
JP2021558405
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-11-20
Filing Date
2020-11-18
Publication Date
2024-11-13
Estimated Expiration
2040-11-18

AI Technical Summary

Benefits of technology

【0010】 本発明の6,7-不飽和-7-カルバモイルモルヒナン誘導体含有製剤は、製剤中にアスコルビン酸類、硫黄を含むアミノ酸類、亜硫酸類、クエン酸類およびリンゴ酸類からなる群から選択される1以上を含有することによって、類縁物質量、特に本製剤を水中に懸濁した後の類縁物質量を低減することができる。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582961000001
    Figure 0007582961000001
  • Figure 0007582961000002
    Figure 0007582961000002
  • Figure 0007582961000003
    Figure 0007582961000003
Patent Text Reader

Abstract

Studies on a variety of stabilizers to improve the stability in water of a compound represented by formula (IA) or a pharmaceutically acceptable salt thereof revealed that a solid formulation having good stability can be provided by preparing a solid formulation containing at least one of ascorbic acid compounds, sulfur-containing amino acids, sulfites, citric acid compounds and malic acid compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a solid preparation containing a 6,7-unsaturated-7-carbamoylmorphinan derivative, in particular, a solid preparation having improved stability of 17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide 4-methylbenzenesulfonic acid. [Background technology]

[0002] Opioid receptor agonists such as morphine are used as very effective analgesics for cancer pain patients, but they induce side effects such as strong nausea, vomiting, constipation, urinary retention, itching, etc. Various antiemetics and anticonstipation drugs are used clinically, but none of them are said to be sufficiently effective, and there is a demand for excellent side effect reducing agents to improve the patient's QOL.

[0003] Patent Document 1 discloses 6,7-unsaturated-7-carbamoylmorphinan derivatives (hereinafter, sometimes referred to as "the derivatives") as agents for reducing the side effects of opioid receptor agonists. Among the derivatives, 17-(cyclopropyl) methyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide 4-methylbenzenesulfonic acid (Compound A, hereinafter sometimes referred to as "this compound") is effective. Patent Document 2 discloses a solid preparation containing this compound.

[0004] Children may take this compound. When children take medicines orally, bitterness may be a problem. In this case, they may take a sweet syrup. In the Japanese Pharmacopoeia General Provisions for Preparations, a syrup is defined as "a viscous liquid or solid preparation containing sugars or sweeteners, administered orally." Among syrups, dry syrups are included as "preparations to be dissolved or suspended when used." Dry syrups are solid and can be dissolved or suspended in water when used, so they have better storage stability and portability than liquids. However, the active ingredient in the dry syrup may decompose after storage over time, and especially when the dry syrup is dissolved or suspended in water, the active ingredient may decompose.

[0005] When the active ingredient in the formulation decomposes, additives may be added to suppress the decomposition. References 1 and 2 do not disclose suppressing the decomposition of the present derivative or compound in water. On the other hand, References 3 to 6 disclose formulations in which the stability of the compound is improved by adding additives. However, the chemical structures of the compounds in these documents and the 6,7-unsaturated-7-carbamoylmorphinan derivatives are significantly different, and it is not disclosed that the stability, especially the stability in water, is improved by adding additives. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] WO2006 / 126637 International Publication Pamphlet [Patent Document 2] WO2013 / 172297 International Publication Pamphlet [Patent Document 3] JP 2009-143948 A [Patent Document 4] Japanese Patent Application Laid-Open No. 11-92369 [Patent Document 5] JP 2014-9226 A [Patent Document 6] Publication of Patent Publication No. 2013-514386 Summary of the Invention [Problem to be solved by the invention]

[0007] Therefore, there has been a demand for development of a formulation which not only enhances the stability of the present derivative or compound, particularly the stability of the present derivative or compound in water, but also has improved stability over time. [Means for solving the problem]

[0008] The present inventors conducted extensive research to improve the stability of formulations containing the derivative or compound, and found an optimal additive, which led to the completion of the present invention. That is, the use of one or more stabilizers selected from the group consisting of ascorbic acids, sulfur-containing amino acids, sulfurous acids, citric acids, and malic acids can increase the stability, particularly in water.

[0009] That is, the present invention (1) an active ingredient of the formula (IA): [ka] or a pharma- ceutical acceptable salt thereof, and further comprising at least one stabilizer selected from the group consisting of ascorbic acids, sulfur-containing amino acids, sulfurous acids, citric acids and malic acids. (2) The solid preparation according to the above (1), wherein the stabilizer is one or more selected from the group consisting of ascorbic acid, sodium L-ascorbate, erythorbic acid, L-cysteine ​​hydrochloride hydrate, L-methionine, sodium pyrosulfite, sodium sulfite, anhydrous citric acid and DL-malic acid. (3) The solid preparation according to the above (1), wherein the stabilizer is one or more selected from the group consisting of ascorbic acid, sodium L-ascorbate, erythorbic acid, L-cysteine ​​hydrochloride hydrate and L-methionine. (4) The solid formulation according to the above (1), wherein the stabilizer is ascorbic acid and / or L-methionine. (5) The solid preparation according to any one of the above (1) to (4), wherein the amount of the stabilizer is 1 to 2500 parts by weight per part by weight of the compound represented by the formula (IA). (6) The solid formulation according to any one of (1) to (5) above, wherein when suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less. (7) The solid preparation according to the above (6), wherein the amount of the hydroxide and / or carboxylate of the compound represented by formula (IA) among the analogues of the compound represented by formula (IA) is 1.0% or less. (8) The solid preparation according to any one of (1) to (7) above, wherein the solid preparation is a granule or a powder. (9) The solid formulation according to (8) above, which can be suspended in water. (10) The solid formulation according to any one of (1) to (9) above, wherein the active ingredient is any one of p-toluenesulfonate, acetate, or hydrochloride of the compound represented by formula (IA). (11) A preparation obtained by suspending the solid preparation according to any one of (1) to (10) above in a liquid. (12) A solid formulation according to any one of (1) to (10) above that can be orally administered, or a liquid-suspended formulation according to (11) above. (13) A method for reducing the amount of related substances of the compound represented by formula (IA) by using ascorbic acid and / or L-methionine, (14) The method according to (13) above, which inhibits an increase in the amount of related substances when suspended in water. Effect of the Invention

[0010] The 6,7-unsaturated-7-carbamoylmorphinan derivative-containing formulation of the present invention can reduce the amount of related substances, particularly the amount of related substances after the formulation is suspended in water, by containing one or more selected from the group consisting of ascorbic acids, sulfur-containing amino acids, sulfurous acids, citric acids, and malic acids in the formulation. BEST MODE FOR CARRYING OUT THEINVENTION

[0011] The opioid receptor agonist side effect reducing agent, which is an active ingredient used in the present invention, is usually a 6,7-unsaturated-7-carbamoylmorphinan derivative, preferably a compound represented by the above formula (IA) (Compound A) or a pharma- ceutical acceptable salt thereof, more preferably a pharma- ceutical acceptable salt of the compound represented by the above formula (IA). Examples of pharma- ceutically acceptable salts of the compound represented by formula (IA) include salts of the compound represented by formula (IA) and alkali metals (e.g., lithium, sodium, potassium, etc.), alkaline earth metals (e.g., calcium, barium, etc.), magnesium, transition metals (e.g., zinc, iron, etc.), ammonia, organic bases (e.g., trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, diethanolamine, ethylene Examples of the salts include salts with diamines, pyridines, picolines, quinolines, etc.) and amino acids, or salts with inorganic acids (e.g., hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid, etc.) and organic acids (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, etc.). In particular, salts with hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, methanesulfonic acid, etc. are included. Salts with acids are preferred. These salts can be formed by a commonly used method. Particularly preferred is a p-toluenesulfonate, acetate or hydrochloride of the compound represented by formula (IA), and more preferably a crystal of the p-toluenesulfonate of the compound represented by formula (IA) or a crystal of a solvate of said salt. Particularly preferred is 17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide 4-methylbenzenesulfonic acid. The p-toluenesulfonic acid crystal of the compound represented by the formula (IA) (Compound A) is non-hygroscopic and has excellent stability, and exists in the crystalline state in a solid preparation. The compound and the method for producing the compound crystal are described in the claims and specifications of the international publications WO2006 / 126637 and WO2012 / 063933.

[0012] The active ingredient in the formulation of the present invention is usually a compound represented by the formula (IA): [ka] or a pharma- ceutical acceptable salt thereof is used. Preferably, the active ingredient is a p-toluenesulfonate, acetate or hydrochloride of the compound represented by formula (IA), more preferably a p-toluenesulfonate of the compound represented by formula (IA).

[0013] Methods for preparing the compound represented by formula (IA), its pharma- ceutically acceptable salts, and the p-toluenesulfonic acid salt of the compound represented by formula (IA) are disclosed in WO 2006 / 126637 and WO 2012 / 063933.

[0014] An example of the p-toluenesulfonic acid salt of the compound represented by formula (IA) is 17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide 4-methylbenzenesulfonic acid.

[0015] The content of the compound represented by formula (IA), the p-toluenesulfonate, acetate or hydrochloride of the compound represented by formula (IA), particularly the compound, which is the derivative of the present invention in the preparation of the present invention, is not particularly limited, but may be an amount that produces a medicinal effect. For example, it is 0.001-10% by weight, preferably 0.001-5% by weight, more preferably 0.001-2.5% by weight, particularly preferably 0.001-2% by weight, based on the total amount of the preparation. If it is more than these blending amounts, the dosage may increase, and if it is less, the amount of decomposition of the active ingredient may increase.

[0016] In order to stabilize the p-toluenesulfonate, acetate or hydrochloride of the present derivative, compound, or compound represented by formula (IA) in the present formulation, the present formulation may contain a stabilizer. The stabilizer may be any that can stabilize the present derivative or compound and is preferably listed in the Japanese Pharmacopoeia, Japanese Pharmacopoeia, Pharmaceutical Additives Standards, Food Additives Official Standards, United States Pharmacopoeia (USP) and European Pharmacopoeia (Ph.Eur.), and is even better if it can be used as an antioxidant. Examples of the additives include ascorbic acids such as ascorbic acid, sodium L-ascorbate, erythorbic acid which is a stereoisomer of ascorbic acid, L-ascorbyl stearate, and L-ascorbyl palmitate; sulfur-containing amino acids such as L-cysteine, L-cysteine ​​hydrochloride, L-cysteine ​​hydrochloride hydrate, L-methionine, and DL-methionine; sulfites such as sodium pyrosulfite and sodium sulfite; citric acids such as anhydrous citric acid, citric acid hydrate, calcium citrate, sodium citrate hydrate, sodium dihydrogen citrate, and disodium citrate; malic acids such as DL-malic acid and sodium DL-malate; and etedoic acids such as sodium etedoate, sodium etedoate hydrate, calcium disodium etedoate, tetrasodium etedoate, and tetrasodium etedoate tetrahydrate. Preferred are ascorbic acids such as ascorbic acid, sodium L-ascorbate, erythorbic acid, a stereoisomer of ascorbic acid, L-cysteine ​​hydrochloride hydrate, sulfur-containing amino acids such as L-methionine, sulfurous acids such as sodium pyrosulfite and sodium sulfite, citric acids such as anhydrous citric acid, and malic acids such as DL-malic acid. More preferred are ascorbic acid, sodium L-ascorbate, erythorbic acid, a stereoisomer of ascorbic acid, L-cysteine ​​hydrochloride hydrate, and sulfur-containing amino acids such as L-methionine. More preferred are ascorbic acid and L-methionine, and particularly preferred is ascorbic acid. These stabilizers may be used alone or in combination of two or more. The additives described above may be used for other purposes in addition to being used as stabilizers.

[0017] The content of the stabilizer in the formulation of the present invention is not particularly limited, but it may be an amount that is small in amount of related substances of the present compound and can stabilize the present compound. For example, the stabilizer is 1-2500 parts by weight, preferably 2-1250 parts by weight, more preferably 3-1000 parts by weight, per 1 part by weight of the present compound, particularly the compound represented by formula (IA), the p-toluenesulfonate, acetate, or hydrochloride of the compound represented by formula (IA). The stabilizer is usually 0.005-30% by weight, preferably 0.01-25% by weight, more preferably 0.1-20% by weight, based on the total amount of the formulation. If the content is greater than these amounts, the dosage may increase, and if the content is less, the active ingredient in the formulation may not be stabilized.

[0018] The analogues of the present compound in the formulation of the present invention are significantly affected by the stabilizer. The main analogues of the present compound include the hydroxylated form of the compound represented by formula (IA) and the carboxylated form of the compound represented by formula (IA).

[0019] The amount of related substances of the compound of the present invention in the formulation of the present invention is 4.0% or less in the initial state, i.e., the total amount of all related substances of the compound represented by formula (IA) (hereinafter, sometimes referred to as "total related substances"). Here, "initial state" refers to the state before the start of the stability test over time. If the amount of related substances is more than this amount, toxicity may occur.

[0020] When the formulation of the present invention is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less. If the amount of related substances is more than this, toxicity may occur.

[0021] When the formulation of the present invention is suspended in water at room temperature for 3 hours, the amount of the hydroxylated compound of the compound represented by formula (IA) or the carboxylated compound of the compound represented by formula (IA) is 1.0% or less. This amount satisfies the safety confirmation threshold of the ICH (International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use) Q3B guideline. If the amount of related substances is more than this, toxicity may occur.

[0022] Even when the formulation of the present invention is stored for one week at 40°C and a relative humidity of 75%, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less, and the amount of the hydroxide of the compound represented by formula (IA) or the carboxylate of the compound represented by formula (IA) is 1.0% or less.

[0023] The preparation of the present invention may contain an excipient, and excipients listed in the Japanese Pharmacopoeia, the Japanese Pharmacopoeia, the Pharmaceutical Additives Standards, the Food Additives Standards, the United States Pharmacopoeia (USP), and the European Pharmacopoeia (Ph.Eur.) can be used. Examples of excipients include sugar derivatives, starch derivatives, cellulose derivatives, inorganic excipients, β-cyclodextrin, magnesium stearate, crospovidone, calcium stearate, sucrose fatty acid esters, powdered tragacanth, gum arabic, dextran, pullulan, etc. Sugar derivatives include sugars and sugar alcohols, and sugars include lactose, sucrose, glucose, fructose, sucrose, maltose, etc., and sugar alcohols include D-mannitol, D-sorbitol, erythritol, xylitol, powdered maltose syrup, maltitol, trehalose, etc. Other sugar derivatives include fructooligosaccharides, palatinose, maltose, reduced maltose, powdered syrup, starch syrup, lactulose, reduced lactose lactitol, and honey sugar. Examples of starch derivatives include starch, potato starch, corn starch, rice starch, partially pregelatinized starch, pregelatinized starch, porous starch, wheat starch, sodium carboxystarch, hydroxypropyl starch, low-substituted carboxymethyl starch, carboxymethyl starch, and the like. Examples of cellulose derivatives include crystalline cellulose, powdered cellulose, carmellose sodium, carmellose, croscarmellose sodium, carmellose calcium, carboxymethylethylcellulose, and low-substituted hydroxypropylcellulose. Examples of inorganic excipients include silicate derivatives, phosphates, carbonates, sulfates, magnesium oxide, titanium oxide, calcium lactate, synthetic hydrotalcite, talc, kaolin, dried aluminum hydroxide, magnesium oxide, and bentonite. Examples of silicate derivatives include hydrous silicon dioxide, silicon dioxide such as light anhydrous silicic acid, magnesium aluminometasilicate, synthetic aluminum silicate, and calcium silicate. Examples of phosphates include anhydrous calcium hydrogen phosphate, anhydrous calcium phosphate, calcium monohydrogen phosphate, calcium hydrogen phosphate, sodium hydrogen phosphate, dipotassium phosphate, potassium dihydrogen phosphate, calcium dihydrogen phosphate, sodium dihydrogen phosphate, and anhydrous silicic acid. Examples of carbonates include precipitated calcium carbonate, calcium carbonate, magnesium carbonate, etc. Examples of sulfates include calcium sulfate, etc. A preferred example of the excipient for the formulation of the present invention is D-mannitol. These excipients may be used alone or in combination of two or more. The additives described above may be used for purposes other than as excipients.

[0024] The particle size of the excipient of the formulation of the present invention may be any particle size that allows the formulation to be manufactured. The particle size of the excipient is a volume average particle size of 1 to 1000 μm, preferably 10 to 750 μm, more preferably 50 to 500 μm, and particularly preferably 75 to 250 μm. If the particle size is larger than this, it may be difficult to manufacture the formulation as a granule or powder, and if the particle size is smaller, the powder may scatter significantly during production, which may affect the content of the active ingredient.

[0025] The content of the excipient in the formulation of the present invention is not particularly limited, but is usually 50-99.9% by weight, preferably 60-99.5% by weight, more preferably 70-99.0% by weight, based on the total amount of the formulation. If the content is less than these amounts, it may be difficult to form the formulation. When two or more excipients are used, the total amount of the excipients may be within the above content range.

[0026] The preparation of the present invention may contain a disintegrant, and disintegrants listed in the Japanese Pharmacopoeia, the Japanese Pharmacopoeia, the Pharmaceutical Additives Standards, the Food Additives Official Code, the United States Pharmacopoeia (USP) and the European Pharmacopoeia (Ph.Eur.) can be used. For example, disintegrants include cellulose-based disintegrants, starch-based disintegrants, vinyl-based disintegrants and magnesium aluminometasilicate. For example, cellulose-based disintegrants include croscarmellose sodium (Ac-Di-Sol), carmellose sodium, carmellose calcium, carmellose, crystalline cellulose, crystalline cellulose-carmellose sodium, low-substituted hydroxypropyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, powdered cellulose and the like. Examples of starch-based disintegrants include sodium carboxymethyl starch, hydroxypropyl starch, corn starch, wheat starch, potato starch, pregelatinized starch, partially pregelatinized starch, corn starch, low-substituted sodium carboxymethyl starch, sodium starch glycolate, and starch. Examples of vinyl-based disintegrants include polyvinylpyrrolidone, crospovidone, and polyvinyl alcohol. Preferred are cellulose-based disintegrants and vinyl-based disintegrants, and in the case of cellulose-based disintegrants, more preferred are sodium salts of croscarmellose sodium, carmellose sodium, crystalline cellulose-carmellose sodium, and carboxymethyl starch sodium. More preferred are croscarmellose sodium and crospovidone, and particularly preferred is croscarmellose sodium. These disintegrants may be used alone or in combination of two or more. In addition, the additives described above may be used for other purposes in addition to being used as disintegrants.

[0027] The content of the disintegrant in the formulation of the present invention is not particularly limited, but is usually 0.01 to 10.0% by weight, preferably 0.05 to 7.5% by weight, more preferably 0.1 to 5.0% by weight, based on the total amount of the formulation. The disintegrant is 1 to 100 parts by weight, preferably 5 to 80 parts by weight, more preferably 10 to 60 parts by weight, based on 1 part by weight of the compound used in the formulation of the present invention. If the content is greater than these amounts, the dosage may increase, and if the content is less, the disintegration and dissolution properties of the formulation may not be sufficient. When two or more disintegrants are used, the total amount of the disintegrants may be within the above content range.

[0028] The formulation of the present invention may contain a suspending agent that suspends the drug in water, and an agent listed in the Japanese Pharmacopoeia, Japanese Pharmacopoeia Non-Drug Standards, Pharmaceutical Excipients Standards, Food Additives Official Compendium, United States Pharmacopoeia (USP), and European Pharmacopoeia (Ph.Eur.) can be used. A suspending agent is also called a suspending agent. For example, the suspending agent may be gum arabic, sodium alginate, kaolin, carrageenan, carboxyvinyl polymer, carmellose, carmellose calcium, carmellose sodium, xanthan gum, glycerin fatty acid ester, light anhydrous silicic acid, crystalline cellulose, crystalline cellulose-carmellose sodium, sucrose fatty acid ester, sorbitan fatty acid ester, hypromellose, hydroxypropyl cellulose, propylene glycol, propylene glycol fatty acid ester, polyvinylpyrrolidone (povidone), polyoxyethylene hydrogenated castor oil, polysorbate 20, polysorbate 60, polysorbate 80, macrogol 4000, macrogol 6000, methylcellulose, ethylene glycol monolaurate, sorbitan monolaurate, polyoxyethylene sorbitan monolaurate, etc. Preferred are hypromellose, hydroxypropyl cellulose, and methylcellulose, more preferably hypromellose and hydroxypropyl cellulose, and particularly preferably hypromellose. These suspending agents may be used alone or in combination of two or more. Furthermore, the additives described above may be used for purposes other than as suspending agents.

[0029] The content of the suspending agent in the formulation of the present invention is not particularly limited, but is usually 0.01 to 10.0% by weight, preferably 0.05 to 5.0% by weight, more preferably 0.1 to 2.5% by weight, based on the total amount of the formulation. The disintegrant is 1 to 100 parts by weight, preferably 2.5 to 50 parts by weight, more preferably 5 to 25 parts by weight, based on 1 part by weight of the compound used in the formulation of the present invention. If the content is more than these amounts, the dosage may increase, and if it is less, the drug may not be sufficiently suspended in water. When two or more suspending agents are used, the total amount of the suspending agents may be within the above content range.

[0030] The preparation of the present invention may contain a binder, and binders listed in the Japanese Pharmacopoeia, Japanese Pharmacopoeia Non-Standards, Pharmaceutical Additives Standards, Food Additives Official Standards, United States Pharmacopoeia (USP), and European Pharmacopoeia (Ph.Eur.) can be used. For example, binders include cellulose-based binders, starch-based binders, vinyl-based binders, polyols, gum arabic, powdered gum arabic, powdered gum arabic, alginic acid, sodium alginate, sucrose, gelatin, dextrin, pullulan, tragacanth, powdered tragacanth, xanthan gum, pectin, sodium polyacrylate, agar, powdered phellodendron bark, guar gum, light anhydrous silicic acid, and hardened oil. Cellulosic binders include carboxymethylcellulose (carmellose, CMC), sodium carboxymethylcellulose (carmellose sodium), hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hypromellose (hydroxypropylmethylcellulose) (HPMC), methylcellulose (MC), crystalline cellulose, microcrystalline cellulose, ethyl cellulose, crystalline cellulose-carmellose sodium, carmellose calcium, powdered cellulose, and low-substituted hydroxypropylcellulose. Examples of starch-based binders include starch, pregelatinized starch, partially pregelatinized starch, potato starch, wheat starch, rice starch, porous starch, corn starch, hydroxypropyl starch, sodium starch glycolate (sodium carboxymethyl starch), and the like. Vinyl-based binders include polyvinyl alcohol (PVA), polyvinylpyrrolidone (povidone) (PVP), carboxyvinyl polymers, copolyvidone, and the like (subcategories). Examples of polyols include macrogol (polyethylene glycol) 200, macrogol 300, macrogol 400, macrogol 600, macrogol 1000, macrogol 1500, macrogol 1540, macrogol 4000, macrogol 6000, macrogol 20000, glycerin, polyoxyethylene

[0105] polyoxypropylene [5] glycol, and propylene glycol. Preferably, it is a cellulose-based binder, more preferably, sodium carboxymethylcellulose (carmellose sodium), hydroxypropylcellulose (HPC), hypromellose (hydroxypropylmethylcellulose), and particularly preferably, hypromellose. These binders may be used alone or in combination of two or more. The additives described above may be used for other purposes in addition to being used as binders.

[0031] The content of the binder in the formulation of the present invention is not particularly limited, but is 0.01 to 10.0% by weight, preferably 0.05 to 5.0% by weight, more preferably 0.1 to 2.5% by weight, based on the total amount of the formulation. In addition, the binder is 1 to 30 parts by weight, preferably 2.5 to 25 parts by weight, more preferably 5 to 20 parts by weight, based on 1 part by weight of the compound used in the formulation of the present invention. If the amount is outside this range, it may be difficult to manufacture the formulation. When two or more binders are used, the total amount of the binders may be within the above content range.

[0032] The formulation of the present invention may contain a lubricant, and lubricants listed in the Japanese Pharmacopoeia, Japanese Pharmacopoeia Non-Standards, Pharmaceutical Additives Standards, Food Additives Official Compendium, United States Pharmacopoeia (USP), and European Pharmacopoeia (Ph.Eur.) can be used. For example, lubricants include stearic acid and metal stearates, inorganic lubricants, hydrophobic lubricants, hydrophilic lubricants, sodium stearyl fumarate, and the like. Examples of stearic acid and metal stearates include magnesium stearate, calcium stearate, stearic acid, stearyl alcohol, polyoxyl 40 stearate, and the like. Examples of inorganic lubricants include talc, light anhydrous silicic acid, hydrous silicon dioxide, magnesium carbonate, precipitated calcium carbonate, dried aluminum hydroxide gel, magnesium aluminometasilicate, magnesium silicate, synthetic aluminum silicate, magnesium oxide, magnesium sulfate, and the like. Examples of hydrophobic lubricants include cacao butter, carnauba wax, glycerin fatty acid esters, hardened oil, white beeswax, hardened soybean oil, beeswax, cetanol, sodium laurate, and sodium stearyl fumarate. Hydrophilic lubricants include sucrose fatty acid esters, polyethylene glycol (macrogol), and the like. Preferred are metal stearates and inorganic lubricants, more preferred are magnesium stearate, calcium stearate, talc, light anhydrous silicic acid, hydrated silicon dioxide, magnesium carbonate, precipitated calcium carbonate, dried aluminum hydroxide gel, magnesium aluminometasilicate, magnesium silicate, synthetic aluminum silicate, magnesium oxide, and magnesium sulfate, and particularly preferred are magnesium stearate and talc. These lubricants may be used alone or in combination of two or more. The additives described above may also be used for other purposes besides as lubricants.

[0033] The content of the lubricant in the formulation of the present invention is not particularly limited, but is 0.01-5.0% by weight, preferably 0.02-2.5% by weight, more preferably 0.05-2.0% by weight, based on the total amount of the formulation. The lubricant is 0.1-50 parts by weight, preferably 0.5-40 parts by weight, more preferably 1-30 parts by weight, based on 1 part by weight of the compound used in the formulation of the present invention. If it is outside this range, the formulation may not flow sufficiently. When two or more kinds of lubricants are used, the total amount of the lubricant may be within the above content range.

[0034] The preparation of the present invention may contain an anti-caking agent to prevent the preparation from caking and to facilitate packaging, transportation and consumption. The additives described in the Japanese Pharmacopoeia, the Japanese Pharmacopoeia, the Pharmaceutical Additives Standards, the Food Additives Standards, the United States Pharmacopoeia (USP) and the European Pharmacopoeia (Ph.Eur.) can be used as the anti-caking agent. For example, the anti-caking agent may be powdered cellulose, sodium stearate, talc, silicon dioxide, colloidal silicon dioxide, calcium silicate, magnesium silicate, magnesium trisilicate, tricalcium phosphate, tricalcium phosphate, magnesium oxide, etc. Talc is preferable. These anti-caking agents may be used alone or in combination of two or more. The additives described above may be used for other purposes in addition to being used as anti-caking agents.

[0035] The content of the caking inhibitor in the formulation of the present invention is not particularly limited, but is 0.1-5.0% by weight, preferably 0.2-2.5% by weight, more preferably 0.25-2.0% by weight, based on the total amount of the formulation. The amount of the caking inhibitor is 0.1-50 parts by weight, preferably 0.5-40 parts by weight, more preferably 1-30 parts by weight, based on 1 part by weight of the compound used in the formulation of the present invention. If the amount is outside this range, the formulation may not flow sufficiently. When two or more types of caking inhibitors are used, the total amount of the caking inhibitors may be within the above content range.

[0036] The preparation may contain a dye or coloring agent, and dyes and coloring agents listed in the Japanese Pharmacopoeia, the Japanese Pharmacopoeia Non-Pharmacopoeial Drug Standards, the Pharmaceutical Additives Standards, and the Food Additives Official Standards can be used. For example, iron oxide, tar dyes, and natural dyes can be mentioned. Examples of iron oxide include ferric oxide, yellow ferric oxide, yellow ferric oxide, and black ferric oxide. Examples of tar dyes include aluminum lake food yellow No. 4, aluminum lake food blue No. 1, aluminum lake food red No. 3, aluminum lake food blue No. 1, food blue No. 2, food yellow No. 4, food yellow No. 5, food red No. 102, food red No. 2, and food red No. 3. Examples of natural dyes include turmeric extract, β-carotene, carotene liquid, sodium copper chlorophyllin, copper chlorophyll, naked barley green leaf extract powder, naked barley green leaf green juice dried powder, naked barley green leaf extract, etc.

[0037] If necessary, the preparation may further contain additives other than those mentioned above, and additives listed in the Japanese Pharmacopoeia, the Japanese Pharmacopoeia Non-Drug Standards, the Pharmaceutical Additives Standards, and the Food Additives Official Codex may be used. The content of these additives may be any ratio. Examples of additives other than those mentioned above include flavorings, flow agents, and flavoring agents. Examples of flavorings include orange essence, orange oil, caramel, camphor, cinnamon oil, spearmint oil, strawberry essence, chocolate essence, cherry flavor, spruce oil, pine oil, peppermint oil, vanilla flavor, bitter essence, fruit flavor, peppermint essence, mixed flavor, mint flavor, menthol, lemon powder, lemon oil, and rose oil. Examples of the fluidizing agent include hydrated silicon dioxide, light anhydrous silicic acid, crystalline cellulose, synthetic aluminum silicate, and talc. Examples of flavoring agents include aspartame, sucralose, glycine, sodium chloride, magnesium chloride, hydrochloric acid, dilute hydrochloric acid, citric acid and its salts, anhydrous citric acid, L-glutamic acid and its salts, succinic acid and its salts, acetic acid, tartaric acid and its salts, sodium bicarbonate, fumaric acid and its salts, malic acid and its salts, glacial acetic acid, disodium inosinate, honey, and the like. The additives can be used alone or in combination in any amount as long as the stability of the active ingredient is not reduced.

[0038] As a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof and a stabilizer. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, a stabilizer, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0039] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof and an ascorbic acid or similar compound. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, an ascorbic acid or similar compound, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0040] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof and an amino acid containing sulfur. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, an amino acid containing sulfur, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0041] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing a compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, and a sulfite. For example, there is a solid preparation containing a compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, a sulfite, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0042] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof and a citric acid or similar compound. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, a citric acid or similar compound, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0043] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof and a malic acid or similar compound. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, a malic acid or similar compound, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0044] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof and ascorbic acid. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, ascorbic acid, and one or more selected from the group consisting of excipients, disintegrants, suspending agents, binders, lubricants, and anti-caking agents.

[0045] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof and sodium L-ascorbate. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, sodium L-ascorbate, and one or more selected from the group consisting of excipients, disintegrants, suspending agents, binders, lubricants, and anti-caking agents.

[0046] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof and erythorbic acid. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, erythorbic acid, and one or more selected from the group consisting of excipients, disintegrants, suspending agents, binders, lubricants, and anti-caking agents.

[0047] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, and L-cysteine ​​hydrochloride hydrate. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, L-cysteine ​​hydrochloride hydrate, and one or more selected from the group consisting of excipients, disintegrants, suspending agents, binders, lubricants, and anti-caking agents.

[0048] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof and L-methionine. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, L-methionine, and one or more selected from the group consisting of excipients, disintegrants, suspending agents, binders, lubricants, and anti-caking agents.

[0049] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof and sodium pyrosulfite. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, sodium pyrosulfite, and one or more selected from the group consisting of excipients, disintegrants, suspending agents, binders, lubricants, and anti-caking agents.

[0050] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof and sodium sulfite. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, sodium sulfite, and one or more selected from the group consisting of excipients, disintegrants, suspending agents, binders, lubricants, and anti-caking agents.

[0051] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, or a solvate of said compound or said salt, and anhydrous citric acid. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, anhydrous citric acid, and one or more selected from the group consisting of excipients, disintegrants, suspending agents, binders, lubricants, and anti-caking agents.

[0052] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing a pharma- ceutically acceptable salt of the compound represented by formula (IA) or a solvate of the compound or the salt, and DL-malic acid. For example, there is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutically acceptable salt thereof, DL-malic acid, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0053] Another embodiment of the solid formulation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid formulation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, a stabilizer, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0054] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, ascorbic acid, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0055] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, sodium L-ascorbate, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0056] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, erythorbic acid, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0057] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, L-cysteine ​​hydrochloride hydrate, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0058] Another embodiment of the solid formulation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid formulation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, L-methionine, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0059] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, sodium pyrosulfite, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0060] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, sodium sulfite, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0061] Another embodiment of the solid formulation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid formulation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, anhydrous citric acid, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0062] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, DL-malic acid, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0063] Another embodiment of the solid formulation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid formulation containing a compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and a stabilizer, and when the solid formulation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0064] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and an ascorbic acid or similar compound, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0065] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and sulfur-containing amino acids, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0066] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing a compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and a sulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0067] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and a citric acid analogue, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0068] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof and malic acid or a similar compound, and the solid preparation is This solid preparation contains not more than 4.0% of the total related substances of the compound of formula (IA) when suspended in water at room temperature for 3 hours.

[0069] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and ascorbic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0070] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and sodium L-ascorbate, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0071] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof and erythorbic acid, This solid preparation contains not more than 4.0% of the total related substances of the compound of formula (IA) when suspended in water at room temperature for 3 hours.

[0072] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and L-cysteine ​​hydrochloride hydrate, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0073] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and L-methionine, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0074] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and sodium pyrosulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0075] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and sodium sulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0076] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and anhydrous citric acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0077] Another embodiment of the solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and DL-malic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0078] The solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient, includes a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and a stabilizer, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxylated form and / or the carboxylated form of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0079] A solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient, is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and an ascorbic acid analogue, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0080] The solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient, includes a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and sulfur-containing amino acids, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxylated form and / or the carboxylated form of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0081] The solid preparation contains the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient, and includes a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and a sulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0082] The solid preparation contains the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient, and includes a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and a citric acid analogue, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0083] The solid preparation contains the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient, and includes a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and malic acids, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxylated form and / or the carboxylated form of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0084] A solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient, is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and ascorbic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0085] A solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, as an active ingredient, and an excipient, is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and sodium L-ascorbate, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0086] The solid preparation contains the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient, and includes a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and erythorbic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxylated form and / or the carboxylated form of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0087] A solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, as an active ingredient, and an excipient, is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and L-cysteine ​​hydrochloride hydrate, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0088] A solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, as an active ingredient, and an excipient, is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and L-methionine, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxylated form and / or the carboxylated form of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0089] A solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, as an active ingredient, and an excipient, is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and sodium pyrosulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0090] A solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, as an active ingredient, and an excipient, is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and sodium sulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0091] A solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof as an active ingredient, and an excipient, is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and anhydrous citric acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0092] A solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, as an active ingredient, and an excipient, is a solid preparation containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof, and DL-malic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxylated form and / or the carboxylated form of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0093] As a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and a stabilizer. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), a stabilizer, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0094] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an ascorbic acid. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), an ascorbic acid, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0095] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an amino acid containing sulfur. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), an amino acid containing sulfur, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0096] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and a sulfite. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), a sulfite, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0097] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and a citric acid. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), a citric acid, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0098] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and a malic acid. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), a malic acid, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0099] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and ascorbic acid. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), ascorbic acid, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0100] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and sodium L-ascorbate. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), sodium L-ascorbate, and one or more selected from the group consisting of excipients, disintegrants, suspending agents, binders, lubricants, and anti-caking agents.

[0101] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and erythorbic acid. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), erythorbic acid, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0102] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and L-cysteine ​​hydrochloride hydrate. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), L-methionine, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0103] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and L-methionine. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), L-methionine, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0104] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and sodium pyrosulfite. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), sodium pyrosulfite, and one or more selected from the group consisting of excipients, disintegrants, suspending agents, binders, lubricants, and anti-caking agents.

[0105] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and sodium sulfite. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), sodium sulfite, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0106] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and anhydrous citric acid. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), anhydrous citric acid, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0107] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and DL-malic acid. For example, there is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), DL-malic acid, and one or more selected from the group consisting of an excipient, a disintegrant, a suspending agent, a binder, a lubricant, and an anti-caking agent.

[0108] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA), a stabilizer, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate and talc.

[0109] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient, and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), ascorbic acid, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0110] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient, and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), sodium L-ascorbate, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0111] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient, and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), erythorbic acid, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0112] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient, and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), L-cysteine ​​hydrochloride hydrate, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0113] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient, and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), L-methionine, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0114] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient, and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), sodium pyrosulfite, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0115] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient, and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), sodium sulfite, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0116] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient, and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA), anhydrous citric acid, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate, and talc.

[0117] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA), DL-malic acid, D-mannitol, croscarmellose sodium, hypromellose, magnesium stearate and talc.

[0118] Another embodiment of the solid formulation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid formulation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and a stabilizer, and when the solid formulation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0119] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and an ascorbic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0120] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and sulfur-containing amino acids, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0121] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and a sulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0122] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and a citric acid or similar compound, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0123] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and malic acids, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0124] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and ascorbic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0125] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and sodium L-ascorbate, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0126] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and erythorbic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0127] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and L-cysteine ​​hydrochloride hydrate, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0128] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and L-methionine, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0129] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and sodium pyrosulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0130] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and sodium sulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0131] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and anhydrous citric acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the total amount of related substances of the compound represented by formula (IA) is 4.0% or less.

[0132] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and DL-malic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the total related substances of the compound represented by formula (IA) is 4.0% or less.

[0133] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and a stabilizer, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0134] Another embodiment of the solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and an ascorbic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0135] Another embodiment of the solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) as an active ingredient and an additive is a solid preparation containing the p-toluenesulfonate of the compound represented by formula (IA) and sulfur-containing amino acids, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0136] A solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive includes a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and a sulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0137] A solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive includes a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and a citric acid analogue, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0138] As a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive, there is a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and malic acids, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0139] A solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive includes a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and ascorbic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0140] A solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive includes a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and sodium L-ascorbate, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0141] A solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive includes a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and erythorbic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0142] A solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive includes a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and L-cysteine ​​hydrochloride hydrate, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0143] A solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive includes a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and L-methionine, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0144] A solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive includes a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and sodium pyrosulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0145] A solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive includes a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and sodium sulfite, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0146] A solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive includes a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and anhydrous citric acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0147] A solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) as an active ingredient and an additive includes a solid preparation containing the p-toluenesulfonate salt of the compound represented by formula (IA) and DL-malic acid, and when the solid preparation is suspended in water at room temperature for 3 hours, the amount of the hydroxide and / or carboxylate salt of the compound represented by formula (IA), among the related substances of the compound represented by formula (IA), is 1.0% or less.

[0148] The dosage form of the preparation of the present invention may be a solid preparation. For example, it may be granules, powders, tablets, fine granules, pills, etc., but is preferably granules or powders. According to the 17th revision of the Japanese Pharmacopoeia, granules are preparations granulated into granules for oral administration, and powders are preparations in powder form for oral administration.

[0149] Among the preparations of the present invention, the method for producing granules or powders is not particularly limited, but can be produced by the following methods. For example, the present compound, granular or powdered excipients, disintegrants and other additives are mixed to produce granules or powders, another embodiment is a method of kneading the mixed powder containing the present compound, excipients, disintegrants and other additives with water and then extrusion granulation, another embodiment is a method of spraying water or the like onto the mixed powder containing the present compound, excipients, disintegrants and other additives, and performing fluidized bed granulation, another embodiment is a method of spraying water or the like onto the mixed powder containing the present compound, excipients, disintegrants and other additives, and performing stirring granulation, another embodiment is a method of spraying water or the like onto the mixed powder containing the present compound, excipients, disintegrants and other additives, and performing rolling granulation, and another embodiment is a method of spraying water or the like onto the mixed powder containing the present compound, excipients, disintegrants and other additives, and performing rolling fluidized granulation, but is not limited thereto. When preparing granules, granulation may be performed using any of organic solvents (ethanol, acetone, ethyl alcohol, propyl alcohol, etc.) and mixed solvents of water and organic solvents, in addition to water. After the granules are produced, they can be coated with a coating agent to coat the granules.

[0150] The average particle size of the formulation of the present invention is not particularly limited, but is 1 to 1000 μm, preferably 5 to 500 μm, more preferably 10 to 250 μm, and particularly preferably 100 μm, in terms of volume average particle size.

[0151] The dosage of the compound represented by formula (IA) in the formulation of the present invention is usually 0.01 to 1.0 mg, preferably 0.2 mg, of the compound administered orally once a day to an adult.

[0152] The preparation of the present invention may be administered orally directly, or may be suspended in water.

[0153] In the preparation of the present invention, no aggregates are visible to the naked eye in the early stages of production.

[0154] The average content of the compound represented by formula (IA) in the preparation of the present invention is 95 to 105%, and the standard deviation of each content is 4.0% or less.

[0155] The dissolution of the preparation of the present invention was tested using the second fluid in accordance with the dissolution test method of the Japanese Pharmacopoeia, and the dissolution rate 15 minutes after the start of the test was 80% or more.

[0156] The formulation of the present invention has good water suspendability. When 5 mL of water is added to about 500 mg of the formulation of the present invention, a visually uniform suspension can be obtained by shaking the container, particularly for about 15 seconds. EXAMPLES

[0157] The present invention will be described in detail below with reference to Examples, Comparative Examples and Reference Examples, but the present invention is not limited thereto. The preparations in the Examples, Comparative Examples and Reference Examples were produced by the following methods.

[0158] (1) Effect of stabilizers in the formulation during a 2-week stability test at 50°C In order to investigate the influence of the stabilizers in the formulations in a time stability test after storage at 50° C. for 2 weeks, the formulations shown in Table 1 were produced. As the stabilizers, the stabilizers of Examples 1, 7, and 9 and Comparative Examples 1 to 9 were used. A. Preparation manufacturing method The tosylate of the compound of formula (IA) was sieved through a 60 mesh sieve. D-mannitol (Pearlitol 100SD, manufactured by ROQUETTE), croscarmellose sodium (AcDiSol, manufactured by FMC), hypromellose (TC-5, manufactured by Shin-Etsu Chemical Co., Ltd.), magnesium stearate (manufactured by MALLINCKRODT) and talc (manufactured by MERCK) were sieved through a 30 mesh sieve. A part of D-mannitol and the tosylate of the compound represented by formula (IA) were premixed in a polyethylene bag and then sieved through a 30 mesh sieve. This mixed powder is hereinafter referred to as "pharmaceutical premix powder." Meanwhile, the wire mesh and the receiving vessel were rinsed with some of the D-mannitol. The D-mannitol used for rinsing was premixed in a polyethylene bag. The raw material premix powder, D-mannitol, croscarmellose sodium, and hypromellose were mixed using an 8LV mixer. Then, magnesium stearate and talc were added and mixed using an 8LV mixer. This mixed powder is hereinafter referred to as the "raw material mixed powder." A part of the mixed powder of the raw materials and the stabilizer were premixed in a plastic bag, and then sieved through a 30 mesh sieve. Then, a part of the mixed powder of the raw materials and the stabilizer were mixed in a plastic bag. In addition, taking into consideration the maximum daily dose of each stabilizer, the stabilizer was blended in the formulation in the amounts shown in Examples 1, 7, and 9 and Comparative Examples 1 to 9 in Tables 2 to 7. In addition, a formulation not blended with a stabilizer was used as Comparative Example 12, and the stability was evaluated.

[0159] [Table 1]

[0160] [Table 2]

[0161] [Table 3]

[0162] [Table 4]

[0163] [Table 5]

[0164] [Table 6]

[0165] [Table 7]

[0166] b. Stability test method The formulation of the present invention was stored in a sealed brown glass bottle for 2 weeks at 50° C. A predetermined amount of the formulation of the present invention was sampled, and the amount of related substances of the compound represented by formula (IA) in the sample was measured. (Sample solution preparation method) 0.5g of sample was taken and placed in a centrifuge tube. 10mL of a solution of 1.0g of stabilizer dissolved in 1000mL of water / methanol (3:1) was accurately measured and placed in the centrifuge tube containing the sample. The centrifuge tube was shaken at room temperature for 5 minutes, and then ultrasonicated for 2 minutes while shaking occasionally. The supernatant after centrifugation (3000rpm, 10 minutes) was filtered with a syringe through a membrane filter (chromatodisk 25N, non-aqueous) with a pore size of 0.45μm, and the initial flow of 3mL was discarded to obtain the sample solution. (Measurement method) The amount of the compound was measured by liquid chromatography using the following method and conditions. Detector: UV spectrophotometer (measurement wavelength: 240 nm) Column: L-column ODS (3 μm packing, 4.6 × 100 mm, Chemicals Evaluation and Research Institute, Japan) Column temperature: constant temperature around 45℃ Mobile phase: 20mmol / L phosphate buffer solution at pH 6.1 / HPLC grade acetonitrile / HPLC grade methanol mixture (13:6:1) Mobile phase flow rate: 1.0mL / min The amount of related substances was calculated as a percentage relative to the total peak area of ​​the chromatogram on the HPLC chart, which was taken as 100%.

[0167] c.Results The preparations of the present invention were stored at 50°C in sealed brown glass bottles for 2 weeks. A predetermined amount of the preparations of the present invention (Examples 1, 7, 9, Comparative Examples 1-9, 12) was collected, and the amount of related substances of the compound represented by formula (IA) in the samples was measured. Table 7 shows the stabilizer, the amount of stabilizer, the maximum amount of each related substance (%), the related substances showing the maximum amount, and the total amount of related substances. As a result, the total amount of related substances was 4.0% or more in Comparative Examples 2, 6, and 8, and the maximum amount of each related substance was 1% or more, while the total amount of related substances in the other Examples 1, 7, 9, Comparative Examples 1, 3-5, 7, 9, and 12 was 4% or less, and the maximum amount of each related substance in Examples 1, 7, 9, Comparative Examples 1, 3, 5, 7, 9, and 12 was 1% or less.

[0168] [Table 8]

[0169] [Table 9]

[0170] [Table 10]

[0171] [Table 11]

[0172] (2) Stability test of formulations in water In order to examine the effect of stabilizers in water on formulations containing the present compound, stability tests in water were carried out on the formulations shown in Tables 2 to 7. A. Preparation manufacturing method The formulations shown in Table 12 were manufactured. A portion of D-mannitol (Pearlitol 100SD (ROQUETTE)) and the tosylate of the compound represented by formula (IA) were premixed in a polyethylene bag and then sieved through a 30 mesh sieve. This mixed powder is hereinafter referred to as "pharmaceutical premixed powder." Meanwhile, the wire mesh and receiving vessel were rinsed with some of the D-mannitol. The D-mannitol used for rinsing was premixed in a polyethylene bag. The raw material premix powder, D-mannitol, croscarmellose sodium (AcDiSol, FMC), and hypromellose (TC-5, Shin-Etsu Chemical Co., Ltd.) were mixed using an 8LV mixer. Then, magnesium stearate (MALLINCKRODT) and talc (MERCK) were added and mixed using an 8LV mixer. Taking into account the maximum daily dosage of each stabilizer, the amounts shown in Tables 2 to 7 were added as stabilizers to the formulation.

[0173] [Table 12]

[0174] b. Stability test method in water The formulation of the present invention may be suspended in water. Therefore, the formulation of the present invention was suspended in tap water and a stabilizer capable of improving the stability was investigated. (Test Method) 1.875 g of a formulation containing the tosylate salt of Compound A and additives other than the stabilizer in Table 1, and a specified amount of stabilizer, were placed in a 100 mL container. Approximately 70 g of tap water was placed in the container and stirred. After stirring, additional tap water was added so that the total amount of tap water added was 75 g, and a suspension was obtained. Three hours after adding the tap water, stirring was performed using a stirrer for 30 seconds, and a sample was taken from the center of the container, and the amount of related substances of the compound represented by formula (IA) in the sample was measured. (Sample solution preparation method) 6 mL of sample was collected with a volumetric pipette and poured into a centrifuge tube. 1.0 g of L-ascorbic acid was dissolved in 400 mL of a water / methanol (150:250) mixture, and 4 mL of the solution was accurately measured and poured into the centrifuge tube containing the sample. The centrifuge tube was shaken at room temperature for 5 minutes, and then ultrasonicated for 2 minutes while shaking occasionally. The supernatant after centrifugation (3000 rpm, 10 minutes) was filtered with a syringe through a membrane filter (chromatodisk 25N, non-aqueous) with a pore size of 0.45 μm, and the initial flow of 3 mL was discarded to obtain the sample solution. (Measurement method) The amount of the compound was measured by liquid chromatography using the following method and conditions. Detector: UV spectrophotometer (measurement wavelength: 240 nm) Column: L-column ODS (3 μm packing, 3.0 × 100 mm, Chemicals Evaluation and Research Institute, Japan) Column temperature: constant temperature around 45℃ Mobile phase: 20mmol / L phosphate buffer solution at pH 6.1 / HPLC grade acetonitrile / HPLC grade methanol mixture (13:6:1) Mobile phase flow rate: 0.4mL / min The amount of related substances was calculated as a percentage relative to the total peak area of ​​the chromatogram on the HPLC chart, which was taken as 100%.

[0175] c.Results Three hours after the formulation of the present invention was added, a sample was taken from the center of the container, and the amount of related substances in the sample represented by formula (IA) was measured. Tables 13 to 18 show the stabilizer, the maximum amount (%) of each related substance, and the related substances that showed the maximum amount. As a result, in the formulations of Examples 1 to 9, the maximum amount of each related substance was less than 1.0%, and this amount satisfied the safety confirmation threshold of the ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use) Q3B guideline. On the other hand, in the formulations of Comparative Examples 1 to 11 and the formulation without a stabilizer (Comparative Example 12), the maximum amount of each related substance was 1.0% or more, and all of them showed high values. In addition, when the preparations of Comparative Examples 1, 3, 5, 7, 9, and 12 were stored at 50°C for 2 weeks, the maximum amount of each related substance was 1.0% or less as described above, but when these preparations were suspended in water at room temperature for 3 hours, the maximum amount of each related substance was 1.0% or more. In addition, depending on the preparation, the related substance that showed the maximum amount was different when stored at 50°C for 2 weeks and when suspended in water for 3 hours. From the above, the stability when suspended in water at room temperature for 3 hours may differ from the stability when stored at 50°C for 2 weeks, and it was considered difficult to predict the stability in water from the stability test over time.

[0176] [Table 13]

[0177] [Table 14]

[0178] [Table 15]

[0179] [Table 16]

[0180] [Table 17]

[0181] [Table 18]

[0182] (3) Stability test of formulations containing ascorbic acid and L-methionine as stabilizers In order to investigate the stability of preparations containing ascorbic acid and L-methionine, which have excellent stabilizer effects, the preparations shown in Table 19 were produced. A. Preparation manufacturing method Raw materials other than the drug substance were sieved through a 30 mesh screen. To produce a mixed powder of D-mannitol and antioxidants, a 2L high-speed mixer (Earth Technica) was used to mix while adding water. The mixture was then dried in a MP-01 dryer (Powrex). This mixed powder is hereafter referred to as the "antioxidant mixed powder." The tosylate of the compound represented by formula (IA) was sieved through a 60 mesh sieve. A portion of D-mannitol and the tosylate of the compound represented by formula (IA) were premixed in a polyethylene bag, and then sieved through a 30 mesh sieve. The wire mesh and receiving container were rinsed with a portion of D-mannitol. The mixture, including the D-mannitol used for rinsing, was premixed in a polyethylene bag. This mixed powder is hereinafter referred to as "pharmaceutical premixed powder." The raw material premix powder, some of the D-mannitol, antioxidant mixed powder, croscarmellose sodium, and hypromellose were mixed in a polyethylene bag. Then, magnesium stearate and talc were added to the bag and mixed.

[0183] [Table 19]

[0184] b. Stability test method (Test Method) The preparation of the present invention was stored in an open brown glass bottle at 40° C. and 75% relative humidity for 1 week. A predetermined amount of the preparation of the present invention was sampled, and the amount of the analogue of the compound represented by formula (IA) in the sample was measured. (Sample solution preparation method) 0.5g of sample was taken and placed in a centrifuge tube. 10mL of a solution of 1.0g of L-ascorbic acid dissolved in 1000mL of a water / methanol (3:1) mixture was accurately measured and placed in the centrifuge tube containing the sample. The centrifuge tube was shaken at room temperature for 5 minutes, and then ultrasonicated for 2 minutes while shaking occasionally. The supernatant after centrifugation (3000rpm, 10 minutes) was filtered with a syringe through a membrane filter (chromatodisk 25N, non-aqueous) with a pore size of 0.45μm, and the initial flow of 3mL was discarded to obtain the sample solution. (Measurement method) The amount of the compound was measured by liquid chromatography using the following method and conditions. Detector: UV spectrophotometer (measurement wavelength: 240 nm) Column: L-column ODS (5 μm packing, 4.6 × 250 mm, Chemicals Evaluation and Research Institute, Japan) Column temperature: constant temperature around 45℃ Mobile phase: 20mmol / L phosphate buffer solution at pH 6.1 / HPLC grade acetonitrile / HPLC grade methanol mixture (13:6:1) Mobile phase flow rate: 1.0mL / min The amount of related substances was calculated using the following formula: Amount of each analogue (%) = M S × (A T × F) / A S × 1 / 200000 × 1 / 0.02604 × 100 / M t M S : Amount (mg) of standard sample of the compound represented by formula (IA) A T : Peak areas of individual related substances other than those derived from the white sample among the peaks eluted after the hydroxide obtained from the sample solution F: Sensitivity coefficient Hydroxide: 1.3, Others: 1.0 A S: Peak area of ​​the compound represented by formula (IA) obtained from the standard solution 1 / 200000: Dilution ratio 0.02604: The amount (mg) of the compound represented by formula (IA) in 1 unit M t :Sample amount (g)

[0185] c.Results The total amount of related substances in the formulations of the present invention, initially and after one week of storage in an opened brown glass bottle at 40°C and 75% relative humidity, is shown in Table 20. Here, "initial" means before the start of the stability test over time. As a result, the total amount of related substances in the formulations of Examples 10 and 11 was 4.0% or less both initially and after one week of storage.

[0186] [Table 20]

[0187] (4) Examination of stabilizer content In order to examine the content of ascorbic acid in the formulations containing the stabilizer ascorbic acid, which would increase the stability of the compound represented by formula (IA) and suppress the production of related substances, the formulations shown in Tables 21 and 22 were produced. A. Preparation manufacturing method Excipients other than the drug substance were sieved through a 30 mesh sieve. The drug substance and a portion of the D-mannitol were mixed in a polyethylene bag and then sieved through a 30 mesh sieve. The wire mesh and receiving container were rinsed with a portion of the D-mannitol and then mixed in the polyethylene bag. The remaining D-mannitol and hypromellose were placed in the bag and mixed in the polyethylene bag. Then, magnesium stearate and talc were placed in the bag and mixed in the polyethylene bag. This mixed powder and a specified amount of ascorbic acid were mixed in a polyethylene bag, then sieved through a 30 mesh sieve and mixed again.

[0188] [Table 21]

[0189] [Table 22]

[0190] b. Stability test method (Test Method) 1.875 g of the present formulation was placed in a 100 mL container. Approximately 70 g of tap water was placed in the container and stirred. After stirring, additional tap water was added so that the total amount of tap water added was 75 g, and a suspension was obtained. Three hours after adding the tap water, the mixture was stirred for 30 seconds using a stirrer, and a sample was taken from the center of the container, and the amount of related substances of the compound represented by formula (IA) in the sample was measured. (Sample solution preparation method) The sample was collected with a 6 mL volumetric pipette and poured into a centrifuge tube. 4 mL of a solution of 1.0 g of L-ascorbic acid dissolved in 400 mL of a water / methanol (150:250) mixture was accurately measured and poured into the centrifuge tube containing the sample. The centrifuge tube was shaken at room temperature for 5 minutes, and then ultrasonicated for 2 minutes while shaking occasionally. The supernatant after centrifugation (3000 rpm, 10 minutes) was filtered with a syringe through a membrane filter (chromatodisk 25N, non-aqueous) with a pore size of 0.45 μm, and the initial flow of 3 mL was discarded to obtain the sample solution. (Measurement method) The amount of the compound was measured by liquid chromatography using the following method and conditions. Detector: UV spectrophotometer (measurement wavelength: 240 nm) Column: L-column ODS (3 μm packing, 3.0 × 100 mm, Chemicals Evaluation and Research Institute, Japan) Column temperature: constant temperature around 45℃ Mobile phase: 20mmol / L phosphate buffer solution at pH 6.1 / HPLC grade acetonitrile / HPLC grade methanol mixture (13:6:1) Mobile phase flow rate: 0.4mL / min (Calculation of the amount of related substances) The amount of related substances was calculated from the following formula. Amount of each analogue (%) = M S × (AT × F) / A S × 1 / 200000 × 1 / 0.02604 × 100 / M t M S : Amount (mg) of standard sample of the compound represented by formula (IA) A T : Peak areas of individual related substances other than those derived from the white sample among the peaks eluted after the hydroxide obtained from the sample solution F: Sensitivity coefficient Hydroxide: 1.3, Others: 1.0 A S : Peak area of ​​the compound represented by formula (IA) obtained from the standard solution 1 / 200000: Dilution ratio 0.02604: The amount (mg) of the compound represented by formula (IA) in 1 unit M t : Amount of formulation contained in a sample taken with a 6 mL volumetric pipette (g)

[0191] c.Results Three hours after the formulation of the present invention was added, a sample was taken from the center of the container, and the amount of related substances in the sample represented by formula (IA) was measured. Table 23 shows the total amount of related substances in Reference Examples 1 to 3 and Examples 12 to 14. As a result, the total amount of related substances was detected in the formulations of Reference Examples 1 to 3, but no related substances were detected in any of the formulations of Examples 12 to 14, which contained 10 mg or more of ascorbic acid in the formulation. Therefore, it was revealed that the total amount of related substances decreased as the amount of ascorbic acid in the formulation increased.

[0192] [Table 23] [Industrial Applicability]

[0193] The stability in water and the time course of the formulation of the present invention containing the compound represented by formula (IA) or a pharma- ceutical acceptable salt thereof have been improved by examining various stabilizers, which allows the formulation of the present invention to be suspended in water, and even children can easily take the formulation of the present invention.

Claims

1. As an active ingredient, the compound of formula (IA): 【Chemistry 1】 and further comprising at least one stabilizer selected from the group consisting of ascorbic acids, sulfur-containing amino acids, and malic acids, The ascorbic acid is ascorbic acid, sodium L-ascorbate, erythorbic acid, L-ascorbyl stearate, and / or L-ascorbyl palmitate; the sulfur-containing amino acids being L-cysteine, L-cysteine ​​hydrochloride, L-cysteine ​​hydrochloride hydrate, L-methionine and / or DL-methionine; A solid formulation, wherein the malic acid derivative is DL-malic acid and / or sodium DL-malate.

2. 2. The solid preparation according to claim 1, wherein the stabilizer is one or more selected from the group consisting of ascorbic acid, sodium L-ascorbate, erythorbic acid, L-cysteine ​​hydrochloride hydrate, L-methionine and DL-malic acid.

3. 2. The solid preparation according to claim 1, wherein the stabilizer is one or more selected from the group consisting of ascorbic acid, sodium L-ascorbate, erythorbic acid, L-cysteine ​​hydrochloride hydrate and L-methionine.

4. 2. The solid preparation according to claim 1, wherein the stabilizer is ascorbic acid and / or L-methionine.

5. The solid preparation according to any one of claims 1 to 4, wherein the amount of the stabilizer is 1 to 2500 parts by weight per part by weight of the compound represented by formula (IA).

6. The solid formulation according to any one of claims 1 to 5, wherein the total amount of analogues of the compound represented by formula (IA) is 4.0% or less when suspended in water at room temperature for 3 hours.

7. 7. The solid preparation according to claim 6, wherein the amount of the hydroxylated form and / or the carboxylated form of the compound represented by formula (IA) among the analogues of the compound represented by formula (IA) is 1.0% or less.

8. The solid preparation according to any one of claims 1 to 7, which is in the form of granules or powder.

9. 9. The solid formulation according to claim 8, which can be suspended in water.

10. A preparation comprising the solid preparation according to any one of claims 1 to 9 suspended in a liquid.

11. The solid formulation according to any one of claims 1 to 9, which can be orally administered, or the liquid-suspended formulation according to claim 10.

12. Ascorbic acid and / or L-methionine produce a compound of formula (IA): 【Chemistry 2】 A method for suppressing an increase in the amount of an analogue of a compound represented by the formula:

13. The method according to claim 12, wherein an increase in the amount of the analogue when suspended in water is suppressed.

Citation Information

Patent Citations

  • Nalmefene injection and preparation method thereof

    CN101406474A

  • Stable methyl naltrexone injection and preparation method thereof

    CN101732243A

  • Pharmaceutical composition of naloxone hydrochloride injection and preparation method thereof

    CN103877016A

  • Naltrexone hydrochloride compositions

    CN1652752A

  • Pharmaceutical preparation, its production and use of acidic additive for stabilization of cilansetron

    JP1999092369A